Europe Sepsis Diagnostics Market

Europe Sepsis Diagnostics Market Size (2023 to 2028)

The size of the sepsis diagnostics market in Europe was valued at USD 430.63 Million in 2023 and is estimated to be worth USD 699.84 Million by 2028, growing at a CAGR of 8.43% during the forecast period.

The increasing prevalence of hospital-acquired infections and the rise in sepsis cases in the European region majorly drive the European sepsis diagnostics market. Hospital-acquired infections such as urinary tract infections, pneumonia and sepsis, pose significant challenges. There have been approximately 3 million reported cases of sepsis in Europe alone. Sepsis is a severe response of the body to infection that can result in organ damage and mortality in some cases. Stringent hygiene measures are crucial to prevent the entry of viruses and infections.

The growing number of advancements in diagnostic devices contributes to the European market growth. Researchers are actively developing point-of-care diagnostic devices for early sepsis detection, addressing the increasing number of cases. Furthermore, investments from private sectors, robust research and development efforts for accurate diagnostic devices and the approval of new products further drive the market growth in Europe.

The rising awareness of sepsis among the European population, increasing number of initiatives from the governments of European countries, technological advancements, increasing demand for rapid and accurate diagnostic solutions and growing support from the European governments for sepsis management contribute to the growth of the European market. The growing aging population leading to a higher risk of sepsis, increasing number of improvements in healthcare infrastructure and facilities, growing number of R&D activities for sepsis, rising emphasis on early detection and timely intervention and growing healthcare expenditure and investment in sepsis diagnostics further promote the growth rate of the European market.

Poor awareness about sepsis and its early symptoms, limited availability of specialized healthcare professionals for sepsis diagnosis, challenges in accurate and timely diagnosis of sepsis and high cost associated with sepsis diagnostic tests and treatments majorly hamper the growth of the European sepsis diagnostics market. Factors such as limited reimbursement policies for sepsis diagnostics, stringent regulatory requirements for sepsis diagnostic products, lack of standardized protocols for sepsis diagnosis and management and limited research funding for sepsis diagnostics further hinder the growth of the European market.

This research report has segmented and sub-segmented the European Sepsis Diagnostics Market into the following categories:

By Pathogen:

• Bacterial Sepsis    
  • Gram-Negative Bacterial Sepsis
  • Gram-Positive Bacterial Sepsis
• Fungal Sepsis        
• Other Pathogen Infections

By Product:

• Instruments          
• Blood Culture Media          
• Assay Kits & Reagents       
• Software  

By Technology:

• Microbiology         
• Molecular Diagnostics       
• Immunoassays    
• Flow Cytometry  
• Other Technologies

By Method:

• Conventional Diagnostics
• Automated Diagnostics

By Usability:

• Laboratory Testing              
• Point-of-Care Testing

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

The European region had a substantial share of the worldwide market in 2022 and is likely to be the second biggest regional market for sepsis diagnostics worldwide during the forecast period.

The UK led the sepsis diagnostics market in Europe in 2022 and is estimated to grow at a healthy CAGR during the forecast period owing to the rising prevalence of infectious and viral diseases and growing healthcare expenditure. The strategic initiatives and regulatory measures to approve advanced sepsis diagnostic devices to facilitate early detection and treatment of sepsis contribute to the UK market growth. The UK government and healthcare organizations have conducted impactful awareness campaigns to educate the population about sepsis symptoms and available treatments, utilizing video-based advertisements. Such factors are predicted to have a favorable impact on the growth rate of the UK market. The sepsis diagnostic market experienced heightened demand during the Covid-19 pandemic as individuals sought diagnostic solutions to detect the virus and other flu infections. Additionally, growing awareness regarding personal care and hygiene practices contributed to the market's growth in the UK. The UK has a higher sepsis-related death rate compared to other countries in Europe. Approximately 48,000 reported deaths annually in the UK. World Sepsis Day is observed on September 13th and serves as an opportunity to raise awareness about sepsis infection in the UK. The UK witnesses around 250,000 sepsis cases each year including cases affecting children. Consequently, there is an increasing demand for sepsis diagnostics in the country, driving the UK market growth.

Germany is projected to account for a notable share of the European market during the forecast period owing to the presence of manufacturing centers specializing in sepsis diagnostic devices. These centers offer cost-effective solutions and ensure affordable prices for sepsis diagnostic tests. The presence of numerous clinical trial centers dedicated to detecting sepsis infections and the continuous evolution of biomarkers in sepsis diagnosis further drive the German market growth.

KEY MARKET PLAYERS:

BioMérieux SA, T2 Biosystem Inc, Cepheid, Thermo Fisher Scientific Inc., Nanosphere Inc, Abbott Laboratories, Roche Diagnostics Limited, Becton, Dickinson and Company, Bruker Corporation and Beckman Coulter, Inc. are some of the major players in the Europe sepsis diagnostics market.